All articles tagged with #phase 3 trials
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, showed superior glycemic control in two Phase 3 trials, outperforming dapagliflozin and oral semaglutide, with significant A1C reductions and weight loss, supporting its potential as a new standard treatment for type 2 diabetes.
Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, potentially making it the first oral PCSK9 inhibitor if approved.
Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, with no major safety concerns, potentially making it the first oral PCSK9 inhibitor if approved.